Structural imaging in late-life depression: association with mood and cognitive responses to antidepressant treatment

Am J Geriatr Psychiatry. 2015 Jan;23(1):4-12. doi: 10.1016/j.jagp.2013.10.001. Epub 2013 Oct 5.

Abstract

Objectives: Recent positron emission tomography studies of cerebral glucose metabolism have identified the functional neural circuitry associated with mood and cognitive responses to antidepressant treatment in late life depression (LLD). The structural alterations in these networks are not well understood. The present study used magnetic resonance (MR) imaging and voxel-based morphometry to evaluate the association between gray matter volumes and changes in mood symptoms and cognitive function with treatment with the antidepressant citalopram.

Design: Open-label trial with baseline brain MR scan. Mood and cognitive assessments performed at baseline and during citalopram treatment.

Setting: Outpatient clinics of an academic medical center.

Participants: 17 previously unmedicated patients age 55 years or older with a major depressive episode and 17 non-depressed comparison subjects.

Intervention: 12-week trial of flexibly dosed citalopram.

Measurements: Gray matter volumes, Hamilton Depression Rating Scale, California Verbal Learning Test, Delis-Kaplan Executive Function System.

Results: In LLD, higher gray matter volumes in the cingulate gyrus, superior and middle frontal gyri, middle temporal gyrus, and precuneus was associated with greater mood improvement. Higher gray matter volumes in primarily frontal areas were associated with greater improvement in verbal memory and verbal fluency performance.

Conclusions: Associations with antidepressant induced improvements in mood and cognition were observed in several brain regions previously correlated with normalization of glucose metabolism after citalopram treatment in LLD. Future studies will investigate molecular mechanisms underlying these associations (e.g., beta-amyloid, inflammation, glutamate).

Keywords: Late-life depression; citalopram; cognition; magnetic resonance imaging; voxel-based morphometry.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Affect / drug effects*
  • Aged
  • Antidepressive Agents, Second-Generation / administration & dosage
  • Antidepressive Agents, Second-Generation / pharmacology*
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology
  • Citalopram / administration & dosage
  • Citalopram / pharmacology*
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / etiology
  • Cognition Disorders / pathology
  • Cognition Disorders / physiopathology
  • Depressive Disorder, Major / complications
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / pathology
  • Depressive Disorder, Major / physiopathology
  • Female
  • Gray Matter / drug effects*
  • Gray Matter / pathology
  • Gray Matter / physiopathology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Antidepressive Agents, Second-Generation
  • Citalopram